NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the Β-catenin pathway

Oncogene

Volumn 31, Issue 20, 2012, Pages 2580-2592

  Thu, Y M ^a   Su, Y ^a   Yang, J ^a   Splittgerber, R ^a   Na, S ^b   Boyd, A ^a   Mosse, C ^a   Simons, C ^a   Richmond, A ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

catenin; melanoma; NIK; survival factors; tumorigenesis

Indexed keywords

BETA CATENIN; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DYSPLASTIC NEVUS; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFORMATION PROCESSING; MELANOMA CELL; METASTATIC MELANOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; STATISTICAL SIGNIFICANCE; SURVIVAL; TISSUE MICROARRAY; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D2; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, MYC; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84861344602     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.427     Document Type: Article

References (61)

1. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. (2007). Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130. (Pubitemid 47199123)
2. Baldwin AS. (2001). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246. (Pubitemid 32157954)
3. Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A. (1991). Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 6: 1115-1124. (Pubitemid 21924197)
4. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. (2002). Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62: 5126-5128. (Pubitemid 35024579)
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
6. Chariot A. (2009). The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 19: 404-413.
7. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. (2010). Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res 23: 27-40.
8. Chin L, Merlino G, DePinho RA. (1998). Malignant melanoma: modern black plague and genetic black box. Genes Dev 12: 3467-3481. (Pubitemid 28553239)
9. Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, Van den Brink GR et al. (2010). Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 70: 8149-8158.
10. Conze DB, Zhao Y, Ashwell JD. (2010). Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biol 8: e1000518.
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
12. Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M et al. (2007). Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21: 2923-2935. (Pubitemid 350133440)
13. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. (2010). Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115: 3541-3552.
14. Devalaraja MN, Wang DZ, Ballard DW, Richmond A. (1999). Elevated constitutive IkappaB kinase activity and IkappaBalpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res 59: 1372-1377. (Pubitemid 29136272)
15. Dhawan P, Richmond A. (2002). A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 277: 7920-7928. (Pubitemid 34968242)
16. Dhomen N, Marais R. (2009). BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23: 529-545, ix.
17. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I et al. (2008). CDK8 is a colorectal cancer oncogene that regulates betacatenin activity. Nature 455: 547-551.
18. Grossman D, Kim PJ, Schechner JS, Altieri DC. (2001). Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98: 635-640. (Pubitemid 32105095)
19. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. (1998). Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512. (Pubitemid 28425575)
20. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R et al. (2008). IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128: 1499-1505. (Pubitemid 351693181)
21. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. (2007). Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144. (Pubitemid 47208626)
22. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. (2003). Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209. (Pubitemid 36859937)
23. Lai AZ, Abella JV, Park M. (2009). Crosstalk in Met receptor oncogenesis. Trends Cell Biol 19: 542-551.
24. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E et al. (2010). Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 102: 1707-1716.
25. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. (2003). Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2: 753-763.
26. Ling L, Cao Z, Goeddel DV. (1998). NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci USA 95: 3792-3797. (Pubitemid 28173208)
27. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D et al. (2001). Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 3: 128-133. (Pubitemid 32118365)
28. Malbon CC. (2005). Beta-catenin, cancer, and G proteins: not just for frizzleds anymore. Sci STKE 2005: pe35.
29. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. (1997). MAP3Krelated kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385: 540-544. (Pubitemid 27074673)
30. McGary EC, Lev DC, Bar-Eli M. (2002). Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 1: 459-465.
31. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109: 707-718. (Pubitemid 34722267)
32. Moore SR, Persons DL, Sosman JA, Bobadilla D, Bedell V, Smith DD et al. (2008). Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14: 2927-2935.
33. Neely RJ, Brose MS, Gray CM, McCorkell KA, Leibowitz JM, Ma C et al. (2010). The RET/PTC3 oncogene activates classical NF-kappaB by stabilizing NIK. Oncogene 30: 87-96.
34. Ng KC, Campos EI, Martinka M, Li G. (2004). XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 123: 1127-1134. (Pubitemid 39586836)
35. Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D et al. (2003). Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 9: 4595-4605. (Pubitemid 37248420)
36. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. (2007). Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12: 445-456. (Pubitemid 350064365)
37. Plenchette S, Cheung HH, Fong WG, LaCasse EC, Korneluk RG. (2007). The role of XAF1 in cancer. Curr Opin Investig Drugs 8: 469-476. (Pubitemid 46868069)
38. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T et al. (2007). c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13: 2246-2253. (Pubitemid 46649894)
39. Puzanov I, Flaherty KT. (2010). Targeted molecular therapy in melanoma. Semin Cutan Med Surg 29: 196-201.
40. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A et al. (2011). Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 331: 468-472.
41. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. (1997). Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792. (Pubitemid 27136716)
42. Ruggero D. (2009). The role of Myc-induced protein synthesis in cancer. Cancer Res 69: 8839-8843.
43. Saitoh Y, Martinez Bruyn VJ, Uota S, Hasegawa A, Yamamoto N, Imoto I et al. (2010). Overexpression of NF-kappaB inducing kinase underlies constitutive NF-kappaB activation in lung cancer cells. Lung Cancer 70: 263-270.
44. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez BV, Iwasaki Y et al. (2008). Overexpressed NF-\{kappa\}B inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Ho. Blood 111: 5118-5129.
45. Scala S, Giuliano P, Ascierto PA, Ierano C, Franco R, Napolitano M et al. (2006). Human melanoma metastases express functional CXCR4. Clin Cancer Res 12: 2427-2433.
46. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P et al. (2005). Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11: 1835-1841. (Pubitemid 40471847)
47. Sinnberg T, Menzel M, Kaesler S, Biedermann T, Sauer B, Nahnsen S et al. (2010). Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. Cancer Res 70: 6999-7009.
48. Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell BM. (2001). NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. J Immunol 167: 5895-5903. (Pubitemid 33062784)
49. Sullivan RJ, Atkins MB. (2009). Molecular-targeted therapy in malignant melanoma. Expert rev anticancer ther 9: 567-581.
50. Van Antwerp DJ, Martin SJ, Verma IM, Green DR. (1998). Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol 8: 107-111.
51. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalphadependent apoptosis. Cell 131: 669-681. (Pubitemid 350087204)
52. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. (2007). IAP antagonists target cIAP1 to induce TNFalphadependent apoptosis. Cell 131: 682-693. (Pubitemid 350103599)
53. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S et al. (2009). Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41: 843-848.
54. Wang CY, Mayo MW, Baldwin Jr AS. (1996). TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 274: 784-787. (Pubitemid 26398259)
55. Wang D, Yang W, Du J, Devalaraja MN, Liang P, Matsumoto K et al. (2000). MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene 19: 4647-4659.
56. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. (2006). BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12: 950-960. (Pubitemid 43259878)
57. Yang J, Pan WH, Clawson GA, Richmond A. (2007). Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res 67: 3127-3134. (Pubitemid 46724849)
58. Yang J, Richmond A. (2001). Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 61: 4901-4909. (Pubitemid 32691908)
59. Yang J, Splittgerber R, Yull FE, Kantrow S, Ayers GD, KarinMet al. (2010). Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest 120: 2563-2574.
60. Yin L, Wu L, Wesche H, Arthur CD, White JM, Goeddel DV et al. (2001). Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 291: 2162-2165. (Pubitemid 32224449)
61. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al. (2001). Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667. (Pubitemid 34013874)